scholarly journals Codon 10 Polymorphisms in the Transforming Growth Factor-Beta 1 Gene May Be Associated With the Predisposition to Idiopathic Pulmonary Fibrosis in Koreans

CHEST Journal ◽  
2010 ◽  
Vol 138 (4) ◽  
pp. 527A
Author(s):  
Ji-Young Son ◽  
Ji-Ye Jung ◽  
Eun-young Kim ◽  
Ju-eun Lim ◽  
Kyung Jong Lee ◽  
...  
Keyword(s):  
Growth Factor ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Growth Factor Beta

scholarly journals A Rnd3/p190RhoGAP pathway regulates RhoA activity in idiopathic pulmonary fibrosis fibroblasts

2018 ◽  
Vol 29 (18) ◽  
pp. 2165-2175 ◽  
Author(s):  
Elizabeth Monaghan-Benson ◽  
Erika S. Wittchen ◽  
Claire M. Doerschuk ◽  
Keith Burridge
Keyword(s):  
Extracellular Matrix ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Normal Lung ◽  
Rhoa Activity ◽  
Incurable Disease ◽  
Normal Lung Function ◽  
Growth Factor Beta

Idiopathic pulmonary fibrosis (IPF) is an incurable disease of the lung that is characterized by excessive deposition of extracellular matrix (ECM), resulting in disruption of normal lung function. The signals regulating fibrosis include both transforming growth factor beta (TGF-β) and tissue rigidity and a major signaling pathway implicated in fibrosis involves activation of the GTPase RhoA. During studies exploring how elevated RhoA activity is sustained in IPF, we discovered that not only is RhoA activated by profibrotic stimuli but also that the expression of Rnd3, a major antagonist of RhoA activity, and the activity of p190RhoGAP (p190), a Rnd3 effector, are both suppressed in IPF fibroblasts. Restoration of Rnd3 levels in IPF fibroblasts results in an increase in p190 activity, a decrease in RhoA activity and a decrease in the overall fibrotic phenotype. We also find that treatment with IPF drugs nintedanib and pirfenidone decreases the fibrotic phenotype and RhoA activity through up-regulation of Rnd3 expression and p190 activity. These data provide evidence for a pathway in IPF where fibroblasts down-regulate Rnd3 levels and p190 activity to enhance RhoA activity and drive the fibrotic phenotype.

The transforming growth factor-beta (TGF-β) family and pulmonary fibrosis

2006 ◽  
Vol 3 (1) ◽  
pp. 99-103 ◽  
Author(s):  
Gail E.M. Martin ◽  
Kjetil Ask ◽  
Sarah E. Gilpin ◽  
Martin Kolb ◽  
Jack Gauldie
Keyword(s):  
Growth Factor ◽  
Pulmonary Fibrosis ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Growth Factor Beta
Sign in / Sign up

Export Citation Format

Share Document